MBX MBX Biosciences Inc revenue, earnings and financials
For the quarter ended June 30, 2026, MBX Biosciences Inc reported revenue of n/a, net income of −$37.1M and diluted EPS of −$0.78; for the fiscal year ended December 2025 revenue was n/a.
MBX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$98.1M, net income −$87.0M (margin n/a), EPS −$2.38
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$68.2M, net income −$61.9M (margin n/a), EPS −$5.82
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$35.3M, net income −$32.6M (margin n/a), EPS −$31.96
MBX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$37.1M, EPS −$0.78
- Quarter ended Mar 31, 2026: revenue n/a, net income −$23.5M, EPS −$0.50
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$22.1M, EPS −$0.46
- Quarter ended Sep 30, 2025: revenue n/a, net income −$21.6M, EPS −$0.63
- Quarter ended Jun 30, 2025: revenue n/a, net income −$19.4M, EPS −$0.58
- Quarter ended Mar 31, 2025: revenue n/a, net income −$23.9M, EPS −$0.71
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$15.6M, EPS $19.84
- Quarter ended Sep 30, 2024: revenue n/a, net income −$18.1M, EPS −$2.78
- Quarter ended Jun 30, 2024: revenue n/a, net income −$15.9M, EPS −$12.62
- Quarter ended Mar 31, 2024: revenue n/a, net income −$12.3M, EPS −$10.26
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$8.84M, EPS n/a
- Quarter ended Sep 30, 2023: revenue n/a, net income −$10.2M, EPS −$9.40
- Quarter ended Jun 30, 2023: revenue n/a, net income −$7.61M, EPS n/a
- Quarter ended Mar 31, 2023: revenue n/a, net income −$5.95M, EPS n/a
MBX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$79.9M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$54.7M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$32.0M, share buybacks n/a
MBX balance sheet
- Jun 30, 2026: cash $54.1M, total assets $436M, total liabilities $26.4M, shareholders' equity $410M
- Mar 31, 2026: cash $45.2M, total assets $453M, total liabilities $14.9M, shareholders' equity $438M
- Dec 31, 2025: cash $75.3M, total assets $385M, total liabilities $15.9M, shareholders' equity $369M
- Sep 30, 2025: cash $223M, total assets $400M, total liabilities $12.5M, shareholders' equity $388M
- Jun 30, 2025: cash $39.8M, total assets $232M, total liabilities $12.3M, shareholders' equity $219M
- Mar 31, 2025: cash $29.9M, total assets $246M, total liabilities $10.5M, shareholders' equity $235M
- Dec 31, 2024: cash $49.4M, total assets $269M, total liabilities $11.1M, shareholders' equity $257M
- Sep 30, 2024: cash $133M, total assets $282M, total liabilities $11.0M, shareholders' equity $271M
Is MBX profitable?
No. MBX Biosciences Inc lost $104M over the last four quarters.
What is MBX's EPS?
Diluted earnings per share over the last four quarters were −$2.37; −$0.78 in the latest quarter.